Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

GLAXOSMITHKLINE PLC Form 6-K July 13, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 12 July 2016

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

--

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

Mr R G Connor

a) Name

President, Global Manufacturing

& Supply

b) Position/status

Initial notification

c) Initial notification/ amendment

Details of the issuer, emission allowance market participant, auction 2 platform, auctioneer or auction monitor

GlaxoSmithKline plc

a) Name

5493000HZTVUYLO1D793

b)LEI

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each

3. place where transaction(s) has been conducted

Description of the financial instrument Ordinary shares of 25 pence

each a)

ISIN: GB0009252882

Acquisition of ordinary shares

under the Company's ShareReward Plan

b) Nature of the transaction

c) Price(s) and volume(s) Price(s) Volume(s)

£16.7127 7 (partnership shares)

7 (matching shares)

£16.7127

Aggregated information

d) 14 Ordinary shares

Aggregated volume Price £16.7127

2016-07-11 (12:18 GMT) e) Date of the transaction

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

f) Place of the transaction

London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant) Date: July 12, 2016

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc